Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Other financing activities (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Other financing activities for 8 consecutive years, with $11000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other financing activities changed N/A to $11000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.9 million, a N/A change, with the full-year FY2023 number at $348000.0, down 54.98% from a year prior.
  • Other financing activities was $11000.0 for Q3 2025 at Plus Therapeutics, down from $773000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $773000.0 in Q4 2022 to a low of $11000.0 in Q3 2025.